CM
AMLX icon

Caption Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Caption Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-150,000
Closed -$285K – 1249
2024
Q2 		$285K Hold
150,000
– – ﹤0.01% 907
2024
Q1 		$426K Buy
+150,000
New +$1.96M 0.01% 906
2023
Q4 		– Sell
-227,800
Closed -$4.17M – 1318
2023
Q3 		$4.17M Buy
227,800
+53,800
+31% +$1.14M 0.06% 365
2023
Q2 		$3.75M Buy
174,000
+159,000
+1,060% +$4.29M 0.07% 352
2023
Q1 		$440K Buy
+15,000
New +$521K 0.01% 812
2022
Q4 		– Sell
-145,000
Closed -$4.08M – 1257
2022
Q3 		$4.08M Buy
145,000
+95,000
+190% +$2.37M 0.06% 410
2022
Q2 		$963K Buy
+50,000
New +$594K 0.01% 891

Other funds holding AMLX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Caption Management's AMLX Position: Q3 2024 in Review

Caption Management sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2024, closing a stake of 1,200 shares — an estimated $2.28K sold.

Caption Management first reported a position in AMLX in Q1 2022 and held it in 7 quarters. The position peaked at $1.63M in Q3 2023. 110 funds tracked by Wall St. Rank hold AMLX as of Q3 2024.

  • Caption Management reported no remaining Amylyx Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Caption Management sold 1,200 Amylyx Pharmaceuticals shares in Q3 2024, an estimated $2.28K.
  • Caption Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 7 quarters.
  • Caption Management's Amylyx Pharmaceuticals position peaked at $1.63M in Q3 2023.
  • 110 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2024.

Based on Caption Management's 13F filing for Q3 2024, filed 14 Nov 2024.